Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David D Stenehjem

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
Melanoma Research|January 29, 2019
Immunotargeted therapy in melanoma: patient, provider preferences, and willingness to pay at an academic cancer centerDavid D Stenehjem, Trang H Au, Surachat Ngorsuraches, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|June 9, 2025
Pharmacogenomics case-based education: Establishment of an Extension for Community Health Outcomes (ECHO) education model for healthcare professionalsPamala A Jacobson, Alyssa N K Johnson, Jeffrey R Bishop, et al.
Plos One|January 26, 2019
Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinomaDavid D Stenehjem, Andrew W Hahn, David M Gill, et al.
Breast Cancer Research and Treatment|January 3, 2021
BRCA testing and outcomes in women with breast cancerDavid D Stenehjem, Claire Telford, Sudhir K Unni, et al.
Cancer Immunology, Immunotherapy : CII|June 10, 2016
Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2David D Stenehjem, Michael Toole, Joseph Merriman, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
Melanoma Research|January 29, 2019
Immunotargeted therapy in melanoma: patient, provider preferences, and willingness to pay at an academic cancer centerDavid D Stenehjem, Trang H Au, Surachat Ngorsuraches, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|June 9, 2025
Pharmacogenomics case-based education: Establishment of an Extension for Community Health Outcomes (ECHO) education model for healthcare professionalsPamala A Jacobson, Alyssa N K Johnson, Jeffrey R Bishop, et al.
Plos One|January 26, 2019
Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinomaDavid D Stenehjem, Andrew W Hahn, David M Gill, et al.
Breast Cancer Research and Treatment|January 3, 2021
BRCA testing and outcomes in women with breast cancerDavid D Stenehjem, Claire Telford, Sudhir K Unni, et al.
Cancer Immunology, Immunotherapy : CII|June 10, 2016
Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2David D Stenehjem, Michael Toole, Joseph Merriman, et al.
Pageof 5